First‐Line Palliative HER2‐Targeted Therapy in HER2‐Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab‐Based Therapy

BACKGROUND. Survival of patients with human epidermal growth receptor 2 (HER2)‐positive metastatic breast cancer (MBC) has improved dramatically since trastuzumab has become available, although the disease eventually progresses in most patients. This study investigates the outcome (overall survival...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Autores principales: Rier, Hánah N., Levin, Mark‐David, van Rosmalen, Joost, Bos, Monique M. E. M., Drooger, Jan C., de Jong, Paul, Portielje, Johanneke E. A., Elsten, Elisabeth M. P., Ten Tije, Albert‐Jan, Sleijfer, Stefan, Jager, Agnes
Formato: Artigo
Lenguaje:Inglês
Publicado: AlphaMed Press 2017
Materias:
Breast Cancer
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5553959/
https://ncbi.nlm.nih.gov/pubmed/28533475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0448
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares